Indian Kanoon - Search engine for Indian Law

placed significant reliance on expert testimony of two kinds - first, on X-ray diffraction tests which establish that Tarceva is Polymorph B alone and second

details of the specification of the aforementioned patent or the x-ray diffraction of the product (tablet) Tarceva or the defendant‟s Erlocip was indicated ... purchased some manufactured in August 2006 from the local market. The x-ray diffraction data of Tarceva sold in India showed that

trial and error experimentations. Moreover, each crystalline form has its own X-ray diffraction pattern. This X-ray diffraction pattern is inherent property of each ... which would lead to the claimed invention. (iv) The x-ray diffraction pattern is an inherent property of each crystalline compound, and the crystalline

temperature of about 25° C; b) an observed powder x-ray diffraction pattern substantially in accordance with the pattern shown in Figure ... simulated powder x-ray diffraction pattern substantially in accordance with the pattern shown in Figure 1, d) a powder x-ray diffraction pattern (CuK alpha

temperature of about 25° C; b) an observed powder x-ray diffraction pattern substantially in accordance with the pattern shown in Figure ... simulated powder x-ray diffraction pattern substantially in accordance with the pattern shown in Figure 1, d) a powder x-ray diffraction pattern (CuK alpha

Astrazeneca Ab & Ors vs P Kumar & Anr on 8 August, 2019 Equivalent citations

Court could have relied on evidence of use of the X-Ray diffraction technique and a consequential analysis of the peaks of both to ascertain ... Erlotinib Hydrochloride. By focusing on evidence involving the analysis of X-Ray diffraction data, the Learned Single Judge has erroneously compared the products of Roche

strain (protein extraction and purification), electrical and wave nature of particles (x-ray diffraction techniques to study active site of enzymes), Biology (animal testing

form of Differential Scanning Calorimetry (DSC)10, Thermogravimetric Analysis11 (TGA) or X-Ray Diffraction (XRD) of Glenmark‟s products. This would have indicated that

infringed. The plaintiffs will also have to disclose to Court the x-ray diffraction data of the product, particularly if it is a pharmaceutical drug ... entire specification of the patent held by the plaintiff together with X-ray diffraction data of Tarceva and Erlocip filed along with the plaint